PMID- 36737488
OWN - NLM
STAT- MEDLINE
DCOM- 20231002
LR  - 20231004
IS  - 1591-9528 (Electronic)
IS  - 1591-8890 (Print)
IS  - 1591-8890 (Linking)
VI  - 23
IP  - 6
DP  - 2023 Oct
TI  - Comparison of the efficacy and safety of selective internal radiotherapy and 
      sorafenib alone or combined for hepatocellular carcinoma: a systematic review and 
      Bayesian network meta-analysis.
PG  - 2141-2150
LID - 10.1007/s10238-023-00997-3 [doi]
AB  - BACKGROUND: Selective internal radiation therapy (SIRT) is a developing technique 
      and its efficacy and modality of application in hepatocellular carcinoma (HCC) 
      are still controversial. This network meta-analysis aims to determine whether the 
      efficacy and safety of SIRT alone and in combination are superior to that of 
      sorafenib. METHODS: Four databases (PubMed, Embase, Cochrane Library, and Web of 
      Science) were searched before August 2022. Cochrane Randomized Trial Risk of Bias 
      Assessment Tool and the Newcastle-Ottawa scale were used to assess the quality. 
      The outcomes of interest included overall survival (OS), progression-free 
      survival (PFS), and adverse events (AEs). RESULTS: A total of 9 eligible trials 
      involving 1954 patients were included, and SIRT ranked first among the three 
      treatment modalities in terms of both OS (probability, 52.3%) and PFS 
      (probability, 68.6%). The combination of SIRT and sorafenib did not improve OS or 
      PFS in patients with HCC. Although the combination of SIRT and sorafenib did not 
      raise the risk of grade 3 or higher AEs, it may have introduced more AEs than 
      either alone. CONCLUSIONS: SIRT alone was found to be superior to sorafenib and 
      the combination of the two in improving OS or PFS in patients with non-surgical 
      HCC, especially in patients with combined portal vein tumor thrombus. The AEs 
      induced by SIRT were different from those of sorafenib, but the overall toxicity 
      was manageable, the combination of the two may cause an increase in the types of 
      AEs that occur.
CI  - (c) 2023. The Author(s).
FAU - Zeng, Hao
AU  - Zeng H
AUID- ORCID: 0000-0001-9609-183X
AD  - Department of Oncology, The Affiliated Hospital of Southwest Medical University, 
      Luzhou, China.
FAU - Zhou, Chengyuan
AU  - Zhou C
AUID- ORCID: 0000-0001-5739-8222
AD  - Southwest Medical University, Luzhou, China.
FAU - Chen, Xiaojing
AU  - Chen X
AUID- ORCID: 0000-0001-5848-3103
AD  - Department of Oncology, The Affiliated Hospital of Southwest Medical University, 
      Luzhou, China.
FAU - Hu, Lanxin
AU  - Hu L
AUID- ORCID: 0000-0003-3662-3827
AD  - Department of Oncology, The Affiliated Hospital of Southwest Medical University, 
      Luzhou, China.
FAU - Su, Ke
AU  - Su K
AUID- ORCID: 0000-0002-7948-6335
AD  - Department of Oncology, The Affiliated Hospital of Southwest Medical University, 
      Luzhou, China.
FAU - Guo, Lu
AU  - Guo L
AD  - Department of Ophthalmology, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, China.
FAU - Han, Yunwei
AU  - Han Y
AUID- ORCID: 0000-0001-8330-0444
AD  - Department of Oncology, The Affiliated Hospital of Southwest Medical University, 
      Luzhou, China. hanyunwei@swmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230203
PL  - Italy
TA  - Clin Exp Med
JT  - Clinical and experimental medicine
JID - 100973405
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/drug therapy/radiotherapy
MH  - Sorafenib/therapeutic use
MH  - *Liver Neoplasms/drug therapy/radiotherapy
MH  - Bayes Theorem
MH  - Network Meta-Analysis
PMC - PMC10543878
OTO - NOTNLM
OT  - Liver cancer
OT  - Network meta-analysis
OT  - Non-surgical treatments
OT  - Transarterial radioembolization
OT  - Yttrium-90
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2023/02/04 06:00
MHDA- 2023/10/02 06:42
PMCR- 2023/02/03
CRDT- 2023/02/03 23:28
PHST- 2022/12/26 00:00 [received]
PHST- 2023/01/12 00:00 [accepted]
PHST- 2023/10/02 06:42 [medline]
PHST- 2023/02/04 06:00 [pubmed]
PHST- 2023/02/03 23:28 [entrez]
PHST- 2023/02/03 00:00 [pmc-release]
AID - 10.1007/s10238-023-00997-3 [pii]
AID - 997 [pii]
AID - 10.1007/s10238-023-00997-3 [doi]
PST - ppublish
SO  - Clin Exp Med. 2023 Oct;23(6):2141-2150. doi: 10.1007/s10238-023-00997-3. Epub 
      2023 Feb 3.